GSK sells non-core assets to Aspen
GlaxoSmithKline is selling its portfolio of anaesthetics and thrombosis business to Aspen as it continues to simplify its business strategy through focusing on core therapeutic areas.
Read More
Tag: anaesthetics
AZ sells anaesthetics portfolio to Aspen
AstraZeneca is selling rights to its global anaesthetics portfolio outside the US to Aspen Global Inc (AGI) in a deal that could be worth $770 million.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
